{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:47:02Z","timestamp":1762508822127},"reference-count":60,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2022.11479","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T11:39:07Z","timestamp":1656589147000},"source":"Crossref","is-referenced-by-count":7,"title":["Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer"],"prefix":"10.3892","volume":"24","author":[{"given":"Xiaoxiang","family":"Jie","sequence":"first","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiayu","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congjian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"key20220825121411_b1-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"key20220825121411_b2-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"key20220825121411_b3-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"h4443","key":"key20220825121411_b4-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4443","article-title":"Diagnosis of ovarian cancer","volume":"351","author":"Sundar","year":"2015","journal-title":"BMJ"},{"key":"key20220825121411_b5-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00404-020-05510-9","article-title":"Ovarian cancer stem cells: Ready for prime time?","volume":"301","author":"Sabini","year":"2020","journal-title":"Arch Gynecol Obstet"},{"issue":"85","key":"key20220825121411_b6-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1077-4","article-title":"Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing","volume":"15","author":"Lee","year":"2015","journal-title":"BMC Cancer"},{"issue":"e1001789","key":"key20220825121411_b7-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and temporal heterogeneity in high-grade serous ovarian cancer: A phylogenetic analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PLoS Med"},{"key":"key20220825121411_b8-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"25520","DOI":"10.18632\/oncotarget.4550","article-title":"The PI3K\/AKT\/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines","volume":"6","author":"Bai","year":"2015","journal-title":"Oncotarget"},{"key":"key20220825121411_b9-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ygyno.2020.04.695","article-title":"Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy","volume":"158","author":"Luo","year":"2020","journal-title":"Gynecol Oncol"},{"key":"key20220825121411_b10-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/path.4105","article-title":"Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease","volume":"229","author":"Castellarin","year":"2013","journal-title":"J Pathol"},{"key":"key20220825121411_b11-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cca.2020.06.047","article-title":"Liquid biopsy in ovarian cancer","volume":"510","author":"Bhardwaj","year":"2020","journal-title":"Clin Chim Acta"},{"key":"key20220825121411_b12-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","article-title":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?","volume":"468","author":"Asante","year":"2020","journal-title":"Cancer Lett"},{"issue":"1251","key":"key20220825121411_b13-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101251","article-title":"Translational application of circulating DNA in oncology: Review of the last decades achievements","volume":"8","author":"Tuaeva","year":"2019","journal-title":"Cells"},{"key":"key20220825121411_b14-ETM-24-3-11479","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20220825121411_b15-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15384047.2018.1504720","article-title":"Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient","volume":"20","author":"Zhou","year":"2019","journal-title":"Cancer Biol Ther"},{"issue":"e6","key":"key20220825121411_b16-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2018.5","article-title":"Potential clinical applications of circulating cell-free DNA in ovarian cancer patients","volume":"20","author":"Barbosa","year":"2018","journal-title":"Expert Rev Mol Med"},{"issue":"djx118","key":"key20220825121411_b17-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"key20220825121411_b18-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.lungcan.2018.05.002","article-title":"Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-na\u00efve advanced non-squamous non-small cell lung cancer patients","volume":"121","author":"Xie","year":"2018","journal-title":"Lung Cancer"},{"issue":"4259293","key":"key20220825121411_b19-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4259293","article-title":"Concordance of genomic alterations between circulating tumor DNA and matched tumor tissue in Chinese patients with breast cancer","volume":"2020","author":"Xu","year":"2020","journal-title":"J Oncol"},{"issue":"1399","key":"key20220825121411_b20-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091399","article-title":"Matched whole-genome sequencing (WGS) and whole-exome sequencing (WES) of tumor tissue with circulating tumor DNA (ctDNA) analysis: Complementary modalities in clinical practice","volume":"11","author":"Imperial","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20220825121411_b21-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jtho.2017.05.011","article-title":"Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small cell lung cancer","volume":"12","author":"Wan","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"572895","key":"key20220825121411_b22-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.572895","article-title":"Detection of EGFR Mutations in cfDNA and CTCs, and comparison to tumor tissue in non-small-cell-lung-cancer (NSCLC) patients","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"key20220825121411_b23-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"85349","DOI":"10.18632\/oncotarget.13350","article-title":"Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer","volume":"7","author":"Kidess-Sigal","year":"2016","journal-title":"Oncotarget"},{"key":"key20220825121411_b24-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.molonc.2016.10.001","article-title":"Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases","volume":"10","author":"Beije","year":"2016","journal-title":"Mol Oncol"},{"key":"key20220825121411_b25-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"72054","DOI":"10.18632\/oncotarget.18679","article-title":"Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer","volume":"8","author":"Chimonidou","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"key20220825121411_b26-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0939-9","article-title":"Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol Cancer"},{"key":"key20220825121411_b27-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/bs.acc.2020.01.001","article-title":"Liquid biopsy in ovarian cancer","volume":"97","author":"Giannopoulou","year":"2020","journal-title":"Adv Clin Chem"},{"key":"key20220825121411_b28-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/biores.2019.0031","article-title":"Comparison of somatic mutation profiles between formalin-fixed paraffin embedded tissues and plasma cell-free DNA from ovarian cancer patients before and after surgery","volume":"9","author":"Jagelkova","year":"2020","journal-title":"Biores Open Access"},{"key":"key20220825121411_b29-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mgg3.414","article-title":"Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer","volume":"6","author":"Du","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"key20220825121411_b30-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4143\/crt.2019.700","article-title":"Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"pl1","key":"key20220825121411_b31-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"key20220825121411_b32-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","article-title":"Advances in targeting Src in the treatment of breast cancer and other solid malignancies","volume":"16","author":"Mayer","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20220825121411_b33-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"key20220825121411_b34-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/mc.22363","article-title":"Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells","volume":"55","author":"Kang","year":"2016","journal-title":"Mol Carcinog"},{"key":"key20220825121411_b35-ETM-24-3-11479","first-page":"818","article-title":"The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression","volume":"19","author":"Zhang","year":"2015","journal-title":"Eur Rev Med Pharmaco"},{"issue":"126","key":"key20220825121411_b36-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0667-6","article-title":"Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: Implications for cancer screening","volume":"14","author":"Cohen","year":"2016","journal-title":"BMC Med"},{"issue":"eaan2415","key":"key20220825121411_b37-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"key20220825121411_b38-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"issue":"1010428320919198","key":"key20220825121411_b39-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1177\/1010428320919198","article-title":"Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study","volume":"42","author":"Alves","year":"2020","journal-title":"Tumour Biol"},{"issue":"e32","key":"key20220825121411_b40-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"key20220825121411_b41-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/1878-0261.12791","article-title":"Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients","volume":"15","author":"Charo","year":"2021","journal-title":"Mol Oncol"},{"issue":"178","key":"key20220825121411_b42-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-021-00860-8","article-title":"Circulating tumor DNA: A noninvasive biomarker for tracking ovarian cancer","volume":"19","author":"Yang","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"issue":"3382","key":"key20220825121411_b43-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113382","article-title":"Comprehensive gene mutation profiling of circulating tumor DNA in ovarian cancer: Its pathological and prognostic impact","volume":"12","author":"Noguchi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"856","key":"key20220825121411_b44-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00856","article-title":"MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA","volume":"9","author":"Salemi","year":"2018","journal-title":"Front Pharmacol"},{"issue":"29831","key":"key20220825121411_b45-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1038\/srep29831","article-title":"Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers","volume":"6","author":"Harris","year":"2016","journal-title":"Sci Rep"},{"key":"key20220825121411_b46-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20220825121411_b47-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ygyno.2018.05.026","article-title":"ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer","volume":"150","author":"Giannopoulou","year":"2018","journal-title":"Gynecol Oncol"},{"key":"key20220825121411_b48-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"21429","DOI":"10.18632\/oncotarget.15249","article-title":"RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA","volume":"8","author":"Giannopoulou","year":"2017","journal-title":"Oncotarget"},{"key":"key20220825121411_b49-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3892\/ol.2020.11356","article-title":"Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer","volume":"19","author":"Noguchi","year":"2020","journal-title":"Oncol Lett"},{"key":"key20220825121411_b50-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-20-3345","article-title":"Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer","volume":"27","author":"Paracchini","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"526","key":"key20220825121411_b51-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.111","article-title":"Prostate cancer: Mutations in ctDNA reflect features of metastatic disease","volume":"14","author":"Sidaway","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"OF8","key":"key20220825121411_b52-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-RW2014-051","article-title":"ctDNA is a specific and sensitive biomarker in multiple human cancers","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"key":"key20220825121411_b53-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"key20220825121411_b54-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metast Rev"},{"key":"key20220825121411_b55-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1517\/14712598.2012.688023","article-title":"The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients","volume":"12 (Suppl 1)","author":"Mouliere","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"OF4","key":"key20220825121411_b56-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2020-013","article-title":"ctDNA reveals targetable alterations","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"key20220825121411_b57-ETM-24-3-11479","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.arcmed.2018.10.007","article-title":"Clinical interest of circulating tumor DNA in oncology","volume":"49","author":"Franczak","year":"2018","journal-title":"Arch Med Res"},{"issue":"53","key":"key20220825121411_b58-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5233","article-title":"A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)","volume":"59","author":"Falzone","year":"2021","journal-title":"Int J Oncol"},{"issue":"7188","key":"key20220825121411_b59-ETM-24-3-11479","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197188","article-title":"An analysis of clinical, surgical, pathological and molecular characteristics of endometrial cancer according to mismatch repair status. A multidisciplinary approach","volume":"21","author":"Dondi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20220825121411_b60-ETM-24-3-11479","first-page":"175","article-title":"Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy","volume":"38","author":"Heudel","year":"2017","journal-title":"Eur J Gynaecol Oncol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:14:37Z","timestamp":1661418877000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2022.11479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,30]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2022.11479","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"542"}}